32,420 Shares of BioMarin Pharmaceutical Inc. $BMRN Bought by First Financial Bank Trust Division

First Financial Bank Trust Division acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the third quarter, Holdings Channel reports. The fund acquired 32,420 shares of the biotechnology company’s stock, valued at approximately $1,945,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC increased its stake in BioMarin Pharmaceutical by 70.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 12,796 shares of the biotechnology company’s stock worth $732,000 after acquiring an additional 5,305 shares during the period. NewEdge Advisors LLC lifted its position in shares of BioMarin Pharmaceutical by 12.1% during the 2nd quarter. NewEdge Advisors LLC now owns 27,287 shares of the biotechnology company’s stock valued at $1,561,000 after acquiring an additional 2,936 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of BioMarin Pharmaceutical by 70.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 187 shares during the period. Corient Private Wealth LP grew its holdings in shares of BioMarin Pharmaceutical by 485.0% during the 2nd quarter. Corient Private Wealth LP now owns 35,525 shares of the biotechnology company’s stock worth $2,033,000 after purchasing an additional 29,452 shares in the last quarter. Finally, Amundi grew its holdings in shares of BioMarin Pharmaceutical by 37.8% during the 2nd quarter. Amundi now owns 259,782 shares of the biotechnology company’s stock worth $14,865,000 after purchasing an additional 71,246 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Down 2.6%

Shares of BioMarin Pharmaceutical stock traded down $1.56 during trading on Thursday, hitting $58.44. The company’s stock had a trading volume of 2,082,177 shares, compared to its average volume of 2,062,336. The stock has a market cap of $11.31 billion, a price-to-earnings ratio of 157.95, a price-to-earnings-growth ratio of 0.43 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The stock has a 50-day moving average price of $64.18 and a two-hundred day moving average price of $58.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period last year, the company earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Oppenheimer boosted their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. William Blair upgraded shares of BioMarin Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd. Jefferies Financial Group raised their price target on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Royal Bank Of Canada decreased their price target on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Finally, Morgan Stanley upped their price objective on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.17.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.